Literature DB >> 23671195

In vivo neurometabolic profiling to characterize the effects of social isolation and ketamine-induced NMDA antagonism: a rodent study at 7.0 T.

Antonio Napolitano1, Khalid Shah, Mirjam I Schubert, Veronica Porkess, Kevin C F Fone, Dorothee P Auer.   

Abstract

Continued efforts are undertaken to develop animal models of schizophrenia with translational value in the quest for much needed novel drugs. Existing models mimic specific neurobiological aspects of schizophrenia, but not its full complexity. Here, we used proton magnetic resonance spectroscopy ((1)H-MRS) to assess the metabolic profile in the prefrontal cortex (PFC) of two established models, rearing in social isolation and acute N-methyl-D-aspartate receptor (NMDA-R) antagonism and their combination. Rats reared in social isolation or group housed underwent (1)H-MRS at baseline and dynamically after ketamine challenge (25mg/kg, intraperitoneal) under isoflurane anesthesia. A 7 T animal scanner was used to perform spectra acquisition from the anterior cingulate/medial PFC. LCModel was used for metabolite quantification and effects of rearing and ketamine injection were analyzed. Social isolation did not lead to significant differences in the metabolic profile of the PFC at baseline. Ketamine induced a significant increase in glutamine in both groups with significance specifically reached by the group-housed animals alone. Only rats reared in social isolation showed a significant 11% γ-aminobutyric acid (GABA) decrease. This study provides preliminary evidence that social interactions in early life predict the glutamatergic and GABAergic response to acute NMDA-R blockade. The similarity between the prefrontal GABA reduction in patients with schizophrenia and in rats reared as social isolates after challenge with ketamine suggests good potential translational value of this combined animal model for drug development.

Entities:  

Keywords:  GABA; NMDA receptor blockade; glutamate; glutamine; ketamine; schizophrenia; social isolation

Mesh:

Substances:

Year:  2013        PMID: 23671195      PMCID: PMC3984514          DOI: 10.1093/schbul/sbt067

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  63 in total

Review 1.  Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.

Authors:  S Miyamoto; G E Duncan; C E Marx; J A Lieberman
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

2.  Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study.

Authors:  Laura M Rowland; Juan R Bustillo; Paul G Mullins; Rex E Jung; Rhoshel Lenroot; Elma Landgraf; Ranee Barrow; Ronald Yeo; John Lauriello; William M Brooks
Journal:  Am J Psychiatry       Date:  2005-02       Impact factor: 18.112

3.  Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex.

Authors:  N Lindefors; S Barati; W T O'Connor
Journal:  Brain Res       Date:  1997-06-13       Impact factor: 3.252

4.  A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia.

Authors:  T U Woo; R E Whitehead; D S Melchitzky; D A Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

5.  Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors:  B Moghaddam; B Adams; A Verma; D Daly
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

6.  Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).

Authors:  F X Vollenweider; K L Leenders; C Scharfetter; A Antonini; P Maguire; J Missimer; J Angst
Journal:  Eur Neuropsychopharmacol       Date:  1997-02       Impact factor: 4.600

Review 7.  In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics.

Authors:  D L Rothman; N R Sibson; F Hyder; J Shen; K L Behar; R G Shulman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-07-29       Impact factor: 6.237

8.  Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia.

Authors:  M A Geyer; L S Wilkinson; T Humby; T W Robbins
Journal:  Biol Psychiatry       Date:  1993-09-15       Impact factor: 13.382

9.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Authors:  J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1994-03

10.  Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release.

Authors:  B Moghaddam; M L Bolinao
Journal:  Synapse       Date:  1994-12       Impact factor: 2.562

View more
  10 in total

1.  Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of 'schizophrenia-like' behaviour in the rat.

Authors:  Philip L R Gaskin; Stephen P H Alexander; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

2.  Anhedonic behavior and γ-amino butyric acid during a sensitive period in female rats exposed to early adversity.

Authors:  Jodi L Lukkes; Shirisha Meda; Kevin J Norman; Susan L Andersen
Journal:  J Psychiatr Res       Date:  2018-02-13       Impact factor: 4.791

Review 3.  Glutamate and GABA Homeostasis and Neurometabolism in Major Depressive Disorder.

Authors:  Ajay Sarawagi; Narayan Datt Soni; Anant Bahadur Patel
Journal:  Front Psychiatry       Date:  2021-04-27       Impact factor: 4.157

4.  Neurobiology of Psychosis and Schizophrenia 2021: Nottingham Meeting.

Authors:  Musa Basseer Sami; Peter Liddle
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 9.306

5.  Characterization of Behavioral, Signaling and Cytokine Alterations in a Rat Neurodevelopmental Model for Schizophrenia, and Their Reversal by the 5-HT6 Receptor Antagonist SB-399885.

Authors:  Sinead E Shortall; Ola H Negm; Maxine Fowler; Lucy C Fairclough; Patrick J Tighe; Peter M Wigmore; Madeleine V King
Journal:  Mol Neurobiol       Date:  2018-02-08       Impact factor: 5.590

Review 6.  The potential of 1H-MRS in CNS drug development.

Authors:  Alice Egerton
Journal:  Psychopharmacology (Berl)       Date:  2019-09-05       Impact factor: 4.530

7.  Glutamine and GABA alterations in cingulate cortex may underlie alcohol drinking in a rat model of co-occurring alcohol use disorder and schizophrenia: an 1H-MRS study.

Authors:  Patrick McCunn; Xi Chen; Barjor Gimi; Alan I Green; Jibran Y Khokhar
Journal:  Schizophrenia (Heidelb)       Date:  2022-08-23

Review 8.  GABA System in Schizophrenia and Mood Disorders: A Mini Review on Third-Generation Imaging Studies.

Authors:  Chiara Chiapponi; Federica Piras; Fabrizio Piras; Carlo Caltagirone; Gianfranco Spalletta
Journal:  Front Psychiatry       Date:  2016-04-19       Impact factor: 4.157

9.  Down-Regulation of Hippocampal Genes Regulating Dopaminergic, GABAergic, and Glutamatergic Function Following Combined Neonatal Phencyclidine and Post-Weaning Social Isolation of Rats as a Neurodevelopmental Model for Schizophrenia.

Authors:  Philip Lr Gaskin; Maria Toledo-Rodriguez; Stephen Ph Alexander; Kevin Cf Fone
Journal:  Int J Neuropsychopharmacol       Date:  2016-12-03       Impact factor: 5.176

Review 10.  Magnetic Resonance Spectroscopy in Schizophrenia: Evidence for Glutamatergic Dysfunction and Impaired Energy Metabolism.

Authors:  João M N Duarte; Lijing Xin
Journal:  Neurochem Res       Date:  2018-04-03       Impact factor: 3.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.